Two clinical cases of adjunctive use of a SGLT-2 inhibitor in type 1 diabetes
Author:
Funder
AstraZeneca
Publisher
Elsevier BV
Subject
Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference16 articles.
1. International Diabetes Federation. IDF Diabetes Atlas, 9th ed. In. Brussels, Belgium; 2019.
2. Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes;Rawshani;New Engl J Med,2017
3. Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study;Rawshani;Lancet (London, England),2018
4. State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018;Foster;Diabetes Technol Ther,2019
5. Patient and disease characteristics of adult patients with type 1 diabetes in Germany: an analysis of the DPV and DIVE databases;van Mark;Ther Adv Endocrinol Metab,2019
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Chronic Treatment with SGLT-2 Inhibitors is Associated with ICU Admission and Disease Severity in Patients with Diabetic Ketoacidosis: A Propensity Score–Matched Cohort Study;2024-09-09
2. Effect of short‐term use of dapagliflozin on impaired awareness of hypoglycaemia in people with type 1 diabetes;Diabetes, Obesity and Metabolism;2021-08-16
3. Dapagliflozin elevates plasma high-density lipoprotein levels and influences visceral fat gene expression in streptozotocin-induced diabetes mellitus;Journal of Pharmacy and Pharmacology;2021-03-22
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3